SVCM
IRWD icon

Saturn V Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Saturn V Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-814,533
Closed -$3.61M – 24
2024
Q4 		$3.61M Sell
814,533
-305,876
-27% -$1.24M 1.41% 18
2024
Q3 		$4.62M Buy
1,120,409
+6,585
+0.6% +$35.4K 1.65% 20
2024
Q2 		$7.26M Buy
1,113,824
+168,912
+18% +$1.19M 2.74% 15
2024
Q1 		$8.23M Buy
+944,912
New +$11.5M 3.3% 15

Other funds holding IRWD

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Saturn V Capital Management's IRWD Position: Q1 2025 in Review

Saturn V Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2025, closing a stake of 814,533 shares — an estimated $3.61M sold.

Saturn V Capital Management first reported a position in IRWD in Q1 2024 and held it in 4 quarters. The position peaked at $8.23M in Q1 2024. 200 funds tracked by Wall St. Rank hold IRWD as of Q1 2025.

  • Saturn V Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 814,533 Ironwood Pharmaceuticals shares in Q1 2025, an estimated $3.61M.
  • Saturn V Capital Management first reported a position in Ironwood Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Saturn V Capital Management's Ironwood Pharmaceuticals position peaked at $8.23M in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2025.

Based on Saturn V Capital Management's 13F filing for Q1 2025, filed 15 May 2025.